Integra LifeSciences Holdings Corporation IART

Full chart Compare
Set alert

Price alert · IART

All alert types
14.82 USD +1.19 (+8.73%)

At closeNov 4, 2026, 4:01 PM EST

14.82 0.00 0.00%

After hours · Nov 4, 4:01 PM ET

13.84 Day range 15.15
8.70 52-week range 20.49
YTD
+19.32%
1 year
+31.15%
Market cap
1.15B
Revenue (ttm)
1.66B
Profit margin
0.79%
EPS (ttm)
0.17
Shares out
77.77M
P/E ratio
87.18
Forward P/E
6.21
YTD return
+19.32%
1-year return
+31.15%
Volume
1.17M
Avg volume
968.85K
Open
13.97
Previous close
13.63
Day's range
13.84 – 15.15
52-week range
8.70 – 20.49
Beta
1.28
Analysts
Hold
Price target
15.67 (+5.7%)
Earnings date
Feb 25, 2027

5Y -57.64 (-79.80%)

2040602022202320242025202614.59

Key statistics

Enterprise value
2.75B
PEG ratio
0.67
Price / sales
0.70
Price / book
1.08
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
2.30%
Free cash flow
106.28M
Total cash
311.93M
Total debt
2.00B
Return on equity
1.24%
Short % of float
12.97%
50-day average
14.71
200-day average
14.08

Financials — quick view

All financials
IART Revenue — quarterly 411.18M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
IART Net income — quarterly 14.85M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
IART EPS — quarterly 0.19
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

IART recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20260.69———
Oct 21, 2026Sep 30, 20260.5570.59+0.03+5.92%
Jul 29, 2026Jun 30, 20260.48050.56+0.08+16.55%
May 5, 2026Mar 31, 20260.410.54+0.13+31.71%
Feb 26, 2026Dec 31, 20250.790.83+0.04+5.06%
Oct 30, 2025Sep 30, 20250.430.54+0.11+25.58%

Upgrades / downgrades

IART analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026UBSmainNeutralNeutral
Oct 26, 2026Truist SecuritiesmainHoldHold
Oct 22, 2026CitigroupmainNeutralNeutral
Oct 22, 2026BMO CapitalmainMarket PerformMarket Perform
Oct 22, 2026Wells FargomainEqual-WeightEqual-Weight
Oct 22, 2026CitizensmainMarket OutperformMarket Outperform

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on IART — it syncs with the Stock Master app.

Insider holders

IART insider holders
InsiderRelationLatest transactionDateShares held
BRADLEY KEITHDirectorStock Award(Grant)May 8, 202589,136
CLAY SHAUNDRADirectorStock Award(Grant)May 8, 202541,515
DAVIS ROBERT T JROfficerStock Award(Grant)Mar 10, 202575,561
ESSIG STUART PH.D.Officer and DirectorStock Award(Grant)May 8, 20251,785,270
GRAVES JEFFREY A.DirectorPurchaseNov 4, 202541,086
HILL BARBARA BENTONDirectorStock Award(Grant)May 6, 2026187,541

Institution ownership

IART institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.73%10,684,103158.34MJun 29, 2026
Rubric Capital Management LP9.97%7,753,934114.91MJun 29, 2026
Invesco Ltd.4.82%3,749,36755.57MJun 29, 2026
Vanguard Portfolio Management LLC4.81%3,743,09355.47MJun 29, 2026
Morgan Stanley4.62%3,593,07953.25MJun 29, 2026
Fuller & Thaler Asset Management Inc.4.42%3,436,00650.92MJun 29, 2026

Fund ownership

IART fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.06%3,933,69658.30MSep 29, 2026
AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund4.36%3,389,02450.23MJul 30, 2026
UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd.3.63%2,822,34341.83MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.71%2,108,29531.24MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.27%1,767,02526.19MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.95%1,515,00222.45MJun 29, 2026